Clindamycin palmitate hydrochloride microbiology

Clindamycin palmitate hydrochloride
CLINDAMYCIN PALMITATE HYDROCHLORIDE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Microbiology

Although clindamycin palmitate HCl is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.

Clindamycin has been shown to have in vitro activity against isolates of the following organisms

Anaerobic gram negative bacilli, including:

Bacteroides species (including Bacteroides fragilis group and Bacteroides melaninogenicus group) Fusobacterium species

Anaerobic gram positive nonsporeforming bacilli, including:

Propionibacterium Eubacterium Actinomyces species

Anaerobic and microaerophilic gram positive cocci, including:

Peptococcus species Peptostreptococcus species Microaerophilic streptococci

Clostridia: Clostridia are more resistant than most anaerobes to clindamycin.

MostClostridium perfringens are susceptible, but other species, e.g., Clostridium sporogenes and Clostridium tertium are frequently resistant to clindamycin. Susceptibility testing should be done.

Cross resistance has been demonstrated between clindamycin and lincomycin. Antagonism has been demonstrated between clindamycin and erythromycin.

References

http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1cb8caa-1e49-41e7-bbd8-a2e75bea2fe4